A national research institute recently opened a new lab and outpost adjacent to the University of Houston's campus. Photo via UH.edu

A national organization has opened a new Houston outpost at a local university campus.

The Electrochemical Safety Research Institute, or ESRI, of UL Research Institutes opened the doors to a new laboratory in Houston in November. The new space was established to further research renewable energy technologies.

“As the world transitions from fossil fuels to sustainable energy, we are working with research teams across several organizations to lay the scientific groundwork for safe and reliable energy storage alternatives,” says Judy Jeevarajan, ESRI’s executive director, in a news release. “Since several of our research partners are based in Houston, the natural progression was to open our own laboratory in the area.”

The lab is housed in the University of Houston Technology Bridge, a startup park next to the university’s main campus. A team of ESRI’s research scientists will have access to explore the safety and performance of renewable energy technologies. Per the release, ESRI already has ongoing projects with UH within hydrogen research, solid-state batteries, and the synthesis of magnesium-ion separators.

“We are significantly expanding both our capacity and scope to better meet today’s increasingly urgent safety challenges,” says Christopher J. Cramer, ULRI’s chief research officer. “Our new Houston facility is one element of that expansion. The lab will strengthen the synergies between ESRI and our research partners in the area and accelerate scientific discoveries to help create a safer, more sustainable world.”

The facility will also act as a homebase for all Houston-area collaborations. Per the release, the new lab "will also facilitate ESRI’s research partnership with Rice University on lithium-ion cell recycling and the research institute’s work with NASA’s Johnson Space Center on thermal runaway mitigation and micro-USB lithium-ion battery safety." The organization also collaborates with Houston-based Stress Engineering Services Inc.

“We’re delighted to welcome the Electrochemical Safety Research Institute to its new home in Houston,” says Chris Taylor, executive director of the Office of Technology Transfer and Innovation at the University of Houston, in the release. “Together, we can build upon our research culture of collaboration as we pursue innovations for the greater good.”

UH has launched its Tech Map, which visualizes startup and innovation activity across the city. Photo via Getty Images

University of Houston launches interactive map of the city's innovation ecosystem

introducing tech map

The greater Houston area spans 9,444 square miles — an area larger than the entire state of New Jersey — and the question was never if Houston's sprawl was going to affect interaction between startups, resources, and opportunities, but how to overcome these physical challenges with digital solutions. The latest of which has launched out of the University of Houston's Technology Bridge.

The Tech Map — an interactive, embeddable visualization that takes data about startups and other innovation players and compiles it into a map of entrepreneurial activity in the Houston area — has officially launched with hundreds of startups represented already.

"This kind of tool — it really tells you where innovation is happening, it's not just in the startup development organizations," says Lindsay Lewis, executive director of communications for the UH Division of Research. "It's amazing to see that it's happening all over the city."

The tool, which is free to embed and available to anyone, is already live on Houston Exponential's homepage and the city of Houston's Innovation Portal. It's comprised of data submitted by startup development organizations, self-submitted information, and research by the Tech Bridge's team.

To be represented on the map, click here.


Lewis stresses the importance of creating the tool in a collaborative way, which is why bringing on partners and their databases was so key. The tool isn't designed in Cougar Red or predominantly feature UH-based startups or anything. The Tech Map isn't meant to rock the boat of what any other organization is doing, rather just visually represent the goings on.

"For us, it was a balance between trying to show the story of Houston and where innovation is happening and aggregating, but what we didn't want to do was be a replacement. We wanted this to be a resource for an individual starting point," says Chris Taylor, executive director for the Tech Bridge. "The biggest challenge for most people is you really don't know where to start."

This year has been one for digital tools focused on better portraying Houston's innovation ecosystem. This summer, Houston Exponential launched the HTX TechList to virtually connect startups, mentors, investors, and other movers and shakers in Houston. The two entities are collaborative — HTX TechList's data is even involved in the Tech Map.

"There was a need for connection," Taylor says. "Since 2013 when I got here, that's always been a challenge and a hurdle. How do we connect all these different stakeholders in a way that's meaningful."

While the map is launched and ready to be used, it's only the beginning for it as it grows its data and adds new features.

"We're not done with this map — this is just the 1.0 version," Lewis says. "We're meeting to talk about next-step functionalities and where we are going to take it."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”